Pricing Log in Create free account

KARDIGAN INC (KARD) vs Mineralys Therapeutics, Inc. (MLYS)

KARDIGAN INC and Mineralys Therapeutics, Inc. are both Biotechnology companies. KARDIGAN INC and Mineralys Therapeutics, Inc. are of similar size ($1.4B and $1.3B). Across the 10 metrics below, KARDIGAN INC leads on 5 and Mineralys Therapeutics, Inc. on 5.

Valuation

Metric KARD MLYS Biotechnology median
P/E n/m n/m 10.60
P/S n/m n/m 9.40
P/B 0.63 2.36 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.82 n/m 0.66
EV/Sales n/m n/m 9.02
Earnings yield (95.11%) (27.62%) (32.88%)
Free cash flow yield (43.18%) (10.68%) (23.13%)

Profitability

Metric KARD MLYS Biotechnology median
Gross margin — — 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (80.88%) (51.96%)
Return on assets 0.00% (69.67%) (46.06%)
Return on invested capital (908.80%) 0.00% 0.00%

Growth

Metric KARD MLYS Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) (68.79%) 37.43% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric KARD MLYS Biotechnology median
Debt to equity 0.00 0.18 0.00
Current ratio 8.72 34.46 4.97
Net debt to EBITDA 1.70 3.85 1.01

Dividend

Metric KARD MLYS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric KARD MLYS Biotechnology median
Market cap 1.30b 1.35b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack